The shift toward "Treat-to-Target" strategies
Under this model, the disease is actively measured using composite scoring systems like the DAS28 (Disease Activity Score) or CDAI (Clinical Disease Activity Index). If a patient does not reach clinical remission or low disease activity within a strict window—typically evaluated every three months, medication regimens are aggressively escalated. This proactive stance prevents structural joint destruction and keeps subclinical inflammation from silently eroding cartilage and bone, even when a patient feels relatively well.
Navigating life after Remission: Maintenance versus cessation
Achieving remission brings forth a complex clinical dilemma: Should successful medication be tapered or stopped entirely? Because rheumatoid arthritis is an autoimmune condition driven by an erratic immune system, stopping disease-modifying anti-rheumatic drugs (DMARDs) often leads to a resurgence of symptoms (Emery et al., 2008).
Clinical studies indicate that while drug-free remission is possible for a small subset of patients, particularly those diagnosed very early who test negative for rheumatoid factor and anti-CCP antibodies, the vast majority experience a relapse if therapy is completely withdrawn. Consequently, rheumatologists usually recommend a cautious tapering approach rather than a complete cessation of care (Nix et al., 2020).
"Remission is attainable for a good number of people if you get diagnosed early and treated aggressively, but sustaining a drug-free remission for more than a year or so is unlikely for most without continued management" (Emery, 2018).
Maintaining a reduced-dose regimen or keeping a baseline maintenance therapy allows patients to protect their hard-won joint stability while minimizing potential long-term side effects.
The horizon of immunology: Toward true eradication
While a permanent cure does not currently exist, the rapid pace of immunological research offers profound hope for the future. Modern drug development has moved far beyond generalized immunosuppression. Scientists are now investigating therapies that target specific cellular pathways, tolerogenic dendritic cells, and antigen-specific immunotherapies designed to "re-educate" the immune system rather than suppress it globally (Firestein & McInnes, 2017).
By identifying the exact triggers that cause the immune system to mistake healthy synovial tissue for an invader, future therapies may eventually switch off the autoimmune response entirely. Until that breakthrough occurs, early diagnosis, aggressive intervention, and sustained remission remain the gold standards of modern rheumatological care, transforming what was once a path of inevitable disability into a manageable, highly treatable condition.
References
Emery, P. (2018). Treatment of rheumatoid arthritis: The potential to cure or just control? Nature Reviews Rheumatology, 14(2), 65–66.
Firestein, G. S., & McInnes, I. B. (2017). Immunopathogenesis of rheumatoid arthritis. Immunity, 46(2), 183–196.
McInnes, I. B., & Schett, G. (2017). The pathogenesis of rheumatoid arthritis. The New England Journal of Medicine, 376(22), 2094–2105.
Nix, D., et al. (2020). Tapering biologic and targeted synthetic DMARDs in rheumatoid arthritis: A systematic review. Seminars in Arthritis and Rheumatism, 50(4), 650–660.
Smolen, J. S., et al. (2016). EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Annals of the Rheumatic Diseases, 76(6), 960–977.
Can Rheumatoid Arthritis Go Into Remission?
This video provides a helpful medical overview from a specialist explaining what achieving clinical remission entails and how treatments like DMARDs and biologics are managed over time.